
| Top 5 Drug Type | Count |
|---|---|
| Small molecule drug | 38 |
| ASO | 3 |
Target |
Mechanism GPD1 modulators [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism caspase 1 agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date21 Aug 2024 |
Sponsor / Collaborator |
Start Date08 May 2023 |
Sponsor / Collaborator |
Start Date15 Jul 2021 |
Sponsor / Collaborator |

| Drug(Targets) | Indications | Global Highest Phase |
|---|---|---|
Resorcylic acid derivatives Compound 1(Yunnan University) | Vancomycin-resistant enterococcal infection More | Preclinical |
K15(Yunnan University) | Vancomycin-resistant enterococcal infection More | Preclinical |
Metformin ( GPD1 x PRKAB1 ) | Subretinal fibrosis More | Preclinical |
Resorcylic acid derivatives Compound 2(Yunnan University) | Vancomycin-resistant enterococcal infection More | Preclinical |
OA derivatives Compound J1(Yunnan University) | Bacterial Infections and Mycoses More | Preclinical |





